On August 12, 2022, Biomedicine and Pharmacotherpy published a
systematic review on the pharmacogenetics of siponimod by Díaz-Villamarín
et al. [1] We would like to acknowledge the work done by the
authors, as siponimod is a drug that may occupy a priority place in the
management of secondarily progressive multiple sclerosis (SPMS) with
active disease evidenced by relapses or imaging features of inflammatory
activity. Therefore, we believe that research aimed at clarifying the
impact of genetic variants on the effectiveness and safety of this drug is
needed; therefore, we applaud the authors’ efforts with this systematic
review.
We consider that there are several inconsistencies in the therapeutic
recommendations contained in the siponimod drug label and in those
issued by the two most relevant international associations in pharmacogenetics:
the Clinical Pharmacogenetics Implementation Consortium
(CPIC) and the Dutch Pharmacogenetics Working Group (DPWG).
